Market Place
Sourcing Support
Japan Approves First Post-Transplant Anti-Cytomegalovirus Infection Treatment
24 Jun 2024 //
BIOSPECTRUM ASIA
Takeda Announces China NMPA Approval of LIVTENCITY for the Treatment of CMV
21 Dec 2023 //
BUSINESSWIRE
Takeda Pharmaceuticals` Livtencity (maribavir) Approved In Europe
05 Jul 2023 //
EMA
Takeda Pharmaceuticals` Livtencity (Maribavir) Receives Approval in Europe
17 Mar 2023 //
EMA
Takeda’s Phase 3 AURORA Study Provides Evidence of Maribavir’s Effect in CMV
19 Dec 2022 //
BUSINESSWIRE
NICE recommends LIVTENCITY for the treatment of adults with post-transplant CMV
09 Dec 2022 //
BIONJ
Eli Lilly`s Livtencity (maribavir) Receives Approval in the Europe
24 Nov 2022 //
EMA
EC Approves maribavir for the Treatment of Adults With CMV Infection
11 Nov 2022 //
PRESS RELEASE
First oral treatment approved for post-transplant refractory cytomegalovirus
11 Nov 2022 //
EUROPEANPHARMACEUTICALREVIEW
Takeda Receives Positive CHMP Opinion for Maribavir CMV
16 Sep 2022 //
BUSINESSWIRE
Takeda Presents New Exploratory Analysis Showing Patients Treated LIVTENCITY
22 Apr 2022 //
BUSINESSWIRE
Takeda’s Phase III CMV infection trial of Livtencity meets primary goal
10 Dec 2021 //
CLINICALTRIALSARENA
Takeda’s Phase III CMV infection trial of Livtencity meets primary goal
09 Dec 2021 //
CLINICALTRIALSARENA
Takeda’s LIVTENCITY Available for Certain Individuals Ages 12 Years and Older
02 Dec 2021 //
BUSINESSWIRE
Takeda`s Livtencity gets US nod for post-transplant CMV infection
23 Nov 2021 //
FIRSTWORDPHARMA
Takeda’s LIVTENCITYTM Approved by FDA in CMV; & more
23 Nov 2021 //
BUSINESSWIRE
Fierce Pharma Asia—Takeda`s cell, gene therapy deals; BMS-BeiGene Abraxane brawl
15 Oct 2021 //
FIERCEPHARMA
FDA panel backs Takeda`s maribavir in transplant patients with CMV infection
08 Oct 2021 //
PHARMAPHORUM
FDA`s ADAC unanimously backs Takeda`s drug for post-transplant cytomegalovirus
08 Oct 2021 //
ENDPTS
FDA offers support for Takeda`s potential cytomegalovirus drug
07 Oct 2021 //
ENDPTS
HRSA orders Boehringer Ingelheim to comply with 340B drug pricing
07 Oct 2021 //
HFN
Takeda`s maribavir clears cytomegalovirus infections in phase 3
12 Feb 2021 //
FIERCEBIOTECH
Takeda’s Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority
11 Feb 2021 //
BUSINESSWIRE
New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug
04 Dec 2020 //
BUSINESSWIRE
New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug
04 Dec 2020 //
PRESS RELEASE
New England Journal of Medicine Ph2 Trial Evaluating Takeda’s TAK-620 Maribavir
24 Sep 2019 //
BUSINESSWIRE
Top 10: Takeda’s late-stage pipeline will rely heavily on Shire drugs
31 Jul 2018 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.